Xenon Pharmaceuticals Inc is a biopharmaceutical company focused on developing treatments for neurological disorders. Based in Canada, it works on innovative therapeutics, including XEN496 and XEN1101, both aimed at treating various forms of epilepsy through the modulation of potassium channels. Additionally, it explores NBI-921352, targeting sodium channels for conditions like SCN8A developmental and epileptic encephalopathy. Collaborating with Neurocrine Biosciences, Xenon is advancing its mission to address unmet medical needs in neurology since 1996.
Two small-cap biotech names made serious noise today. Xenon Pharmaceuticals (XENE) is trading at $62.76, up 49.6% today, while Relmada Therapeutics (RLMD) sits at $7.17, also up 61.1% Both moves were absolutely eye-popping, but…
The biotech sector is one that’s become red-hot, at least in recent years. After around a decade of stagnation, investors appear to be intent on increasing their exposure to top biotech names…
